A randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-894 in adults with attention deficit-hyperactivity disorder (ADHD)
Latest Information Update: 08 Nov 2013
At a glance
- Drugs Sofinicline (Primary) ; Atomoxetine
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 20 Jun 2008 Positive results reported in a NeuroSearch media release.
- 01 Aug 2007 Primary endpoint 'Conners'-Attention-Deficit-Hyperactivity-Disorder-Rating-Scale' has been met.
- 08 Mar 2007 Status changed from recruiting to in progress